Search - tctmd.com

Displaying 181 - 200 of 210

Sort: Relevancy | Date

Presentation CICT 2015

TAVR and cerebral protection: case presentation and evidence update

Presenter: Antonio Colombo

August 01, 2015

Presentation TVT 2015

Cerebral Protection Devices Are Still Meaningful and Necessary

Presenter: Eberhard Grube

June 05, 2015

Presentation ICI 2014

Mechanical Cerebral Protection during TAVR -‐ Current Evidence

Presenter: Andreas Baumbach

December 14, 2014

Presentation ICI 2014

Cerebral Protection During TAVR Study Design and Results of the DEFLECT II Trial

Presenter: P. R. Stella

December 14, 2014

Presentation TCT 2014

Carotid Artery Stenting with Double Cerebral Embolic Protection in Symptomatic Patients

Presenter: Ferdinando Varbella

September 16, 2014

Presentation TCT 2014

TCT 548: Proximal Occlusion Versus Distal Filter for Cerebral Protection During Carotid Stenting: A Meta-analysis of MRI Studies

Presenter: Leo Nelson Hopkins, Sriram S. Iyer, Zvonimir Krajcer, Salvatore Cassese, MD

September 13, 2014

Presentation TCT 2014

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Patrick W. Serruys, David J. Cohen, Axel Linke

September 13, 2014

Presentation TVT 2014

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Presenter: Axel Linke

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will Become the Standard of Care

Presenter: Eberhard Grube

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

Has Stroke Frequency Declined After TAVR?

Presenter: Nicolas M. van Mieghem

June 07, 2014

Presentation TVT 2014

Perspectives from the US CoreValve Trials

Presenter: Jeffrey J. Popma

June 07, 2014

Presentation TVT 2014

Perspectives from the PARTNER Trials

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Presenter: Samir R. Kapadia

June 07, 2014

Presentation TVT 2014

Technology Overview and Clinical Trial Status (DEFLECT I and Other Trials)

Presenter: Alexandra J. Lansky

June 06, 2014

Presentation TVT 2014

Introduction to the US FDA-Approved Sentinel TAVR Safety and Efficacy Study

Presenter: Susheel Kodali

June 06, 2014

Presentation TVT 2014

Histo-Pathology Debris Analysis and Status of the MISTRAL C Randomized Trial

Presenter: Nicolas M. van Mieghem

June 06, 2014

Presentation TVT 2014

Technology Overview and Status of the CLEAN-TAVI Randomized Trial

Presenter: Axel Linke

June 06, 2014

Presentation TVT 2014

Technology Overview and Clinical Trial Status (Pilot Phase of PROTAVI C and Beyond)

Presenter: Alec S. Vahanian

June 06, 2014

Presentation TCT 2013

My Crystal Ball: Procedural Changes (eg, No Predilatation and Cerebral Protection Devices) Will Reduce Strokes After TAVR in the Future

Presenter: Nicolas van Mieghem

October 28, 2013

Advertisement

TAVR and cerebral protection: case presentation and evidence update

Cerebral Protection Devices Are Still Meaningful and Necessary

Mechanical Cerebral Protection during TAVR -‐ Current Evidence

Cerebral Protection During TAVR Study Design and Results of the DEFLECT II Trial

Carotid Artery Stenting with Double Cerebral Embolic Protection in Symptomatic Patients

TCT 548: Proximal Occlusion Versus Distal Filter for Cerebral Protection During Carotid Stenting: A Meta-analysis of MRI Studies

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Why Cerebral Protection after TAVR Will Become the Standard of Care

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Has Stroke Frequency Declined After TAVR?

Perspectives from the US CoreValve Trials

Perspectives from the PARTNER Trials

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Technology Overview and Clinical Trial Status (DEFLECT I and Other Trials)

Introduction to the US FDA-Approved Sentinel TAVR Safety and Efficacy Study

Histo-Pathology Debris Analysis and Status of the MISTRAL C Randomized Trial

Technology Overview and Status of the CLEAN-TAVI Randomized Trial

Technology Overview and Clinical Trial Status (Pilot Phase of PROTAVI C and Beyond)

My Crystal Ball: Procedural Changes (eg, No Predilatation and Cerebral Protection Devices) Will Reduce Strokes After TAVR in the Future

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content